Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported Q4 EPS of ($0.49), $0.16 better than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Contineum Therapeutics, Inc. (CTNM) click here.